Medicinal Chemistry, Rega Institute for Medical Science, KU Leuven, Herestraat 49, PO Box 1030, 3000, Leuven, Belgium.
Laboratory of Optics and Biosciences, INSERM U 696-CNRS UMR 7645, Ecole Polytechnique, Route de Saclay, 91128, Palaiseau Cedex, France.
ChemMedChem. 2019 Mar 22;14(6):645-662. doi: 10.1002/cmdc.201800739. Epub 2019 Feb 20.
Since the discovery of a flavin-dependent thymidylate synthase (ThyX or FDTS) that is absent in humans but crucial for DNA biosynthesis in a diverse group of pathogens, the enzyme has been pursued for the development of new antibacterial agents against Mycobacterium tuberculosis, the causative agent of the widespread infectious disease tuberculosis (TB). In response to a growing need for more effective anti-TB drugs, we have built upon our previous screening efforts and report herein an optimization campaign of a novel series of inhibitors with a unique inhibition profile. The inhibitors display competitive inhibition toward the methylene tetrahydrofolate cofactor of ThyX, enabling us to generate a model of the compounds bound to their target, thus offering insight into their structure-activity relationships.
自发现黄素依赖性胸苷酸合成酶(ThyX 或 FDTS)以来,这种酶在人类中不存在,但对多种病原体的 DNA 生物合成至关重要,因此该酶一直被用于开发针对结核分枝杆菌(导致广泛传染病结核病(TB)的病原体)的新型抗菌药物。为了满足对更有效的抗结核药物的日益增长的需求,我们在以前的筛选工作的基础上,报告了一种具有独特抑制谱的新型抑制剂系列的优化研究。抑制剂对 ThyX 的亚甲基四氢叶酸辅因子表现出竞争性抑制作用,使我们能够生成化合物与靶标结合的模型,从而深入了解其结构-活性关系。